KIT and thyroid cancer: Anlotinib (a multi-target inhibitor that inhibits VEGFR, FGFR, PDGFR, and c- Kit) can significantly inhibit the growth and metastasis of ATC cells and induce the apoptosis of thyroid cancer cells (25).